MktsMarkets

Gain Therapeutics, Inc.
NASDAQ: GANXKey statistics
GANX News
Stories mentioning GANX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 2,763 | 2,347 | 2,850 | 2,759 | 2,257 | 1,224 | 2,622 | 4,438 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 5,354 | 4,466 | 4,786 | 5,090 | 4,369 | 3,331 | 4,459 | 8,183 |
| Operating Income (Loss) | (5,354) | (4,466) | (4,786) | (5,090) | (4,369) | (3,331) | (4,459) | (8,183) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (5,426) | (4,467) | (4,735) | (5,668) | (4,430) | (3,263) | (4,475) | (8,142) |
| Tax Provision | 183.00 | 70.00 | 549.00 | 141.00 | 101.00 | 505.00 | 11.00 | 1.00 |
| Net Income (Loss) | (5,609) | (4,538) | (5,284) | (5,809) | (4,530) | (3,768) | (4,486) | (8,143) |
| Earnings Per Share (Basic) | (0.13) | (0.14) | (0.15) | (0.19) | (0.16) | (0.16) | (0.17) | (0.42) |
| Earnings Per Share (Diluted) | (0.13) | (0.14) | (0.15) | (0.19) | (0.16) | (0.16) | (0.17) | (0.42) |
| Weighted Average Shares Outstanding (Basic) | 42,230 | 32,968 | 34,998 | 30,342 | 28,685 | 22,881 | 26,532 | 19,216 |
| Weighted Average Shares Outstanding (Diluted) | 42,230 | 32,968 | 34,998 | 30,342 | 28,685 | 22,881 | 26,532 | 19,216 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About GANX
Gain Therapeutics, Inc. (NASDAQ: GANX) is a stock listed on the Nasdaq Stock Market under the ticker symbol GANX. It last traded at $1.11 (Nov 18, 2026, 4:00 PM ET), down 5.9% on the day. That gives Gain Therapeutics a market capitalisation of $49.4M.
Over the past 52 weeks GANX has traded between $0.9400 and $4.34.
For the quarter ended Mar 31, 2026 it reported a net loss of $5.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$5.6M |
| Dec 31, 2025 | — | -$4.5M |
| Sep 30, 2025 | — | -$5.3M |
| Jun 30, 2025 | — | -$5.8M |
From Gain Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…